ClinicalTrials.gg
CompletedNCT06588738ONWARD2Updated Oct 28, 2026

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

A Phase 3 interventional study of Envudeucitinib and Placebo in Plaque Psoriasis, sponsored by Alumis Inc. Completed at 124 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Alumis Inc · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2026.
Updated Oct 28, 202610 sites added10 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
862
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
41st of 673
862 · median 77
Started
2024
with 15 others
Phase 3
188 of 764
6 open now
Registered
722nd of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 41st largest by enrollment of the 673 interventional ones that give a count, is one of 16 that started in 2024, is one of 188 in phase 3, and was the 722nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:

  • Does ESK-001 reduce the severity of people's psoriasis?
  • How safe is ESK-001 in people with moderate to severe plaque psoriasis?

The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis).

People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe.

Participants will:

  • take drug every day for 24 weeks.
  • visit the clinic for checkups and tests.
  • fill out questionnaires about their psoriasis, itch severity, and change in quality of life.
  • be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health.
  • provide blood and urine samples.
03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, age ≥18 years
  2. Diagnosis of plaque psoriasis for ≥6 months
  3. Plaques covering ≥10% of BSA
  4. PASI ≥12
  5. sPGA ≥3
  6. Women of (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of

Exclusion criteria

Exclusion Criteria:

  1. Nonplaque psoriasis or other inflammatory skin conditions
  2. Immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Patients with psoriatic arthritis may participate
  3. Pregnant, lactating, or planning to get pregnant during the study
  4. Use of drugs prior to Study Day 1 that treat or may affect psoriasis:

    • Topical within 2 weeks
    • Phototherapy or any systemic treatments within 4 weeks
    • Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months
    • Systemic or immunomodulatory drugs within 4 weeks
    • Modulators of B cells within 6 months, or T cells within 3 months
    • JAK inhibitors or TYK2 inhibitors within 4 weeks
    • PDE4 inhibitor within 2 months
    • Any agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study
  5. Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment
  6. Patients with >450 msec (males) or >470 msec (females) at Screening
  7. Unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months
  8. Evidence of recent or recurrent herpes zoster or herpes simplex viral infection
  9. Evidence of active infection or positive test result for , , or TB
  10. History of serious bacterial, fungal, or viral infections that led to hospitalization, or any recent serious infection requiring antibiotic treatment
  11. Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the patient's immune status
  12. Lab abnormalities indicating significant renal, hepatic or bone marrow dysfunction
  13. History of any immune-mediated or inflammatory medical condition for which patient requires current systemic
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
862 participants (actual)

Study arms

  • Experimental
    ESK-001

    ESK-001 administered as an oral tablet

    Drug: Envudeucitinib

  • Placebo comparator
    Placebo

    Matching oral placebo

    Drug: Placebo

  • Active comparator
    Apremilast

    Apremilast administered as an oral capsule

    Drug: Apremilast

Interventions

06

What researchers measure

Primary outcomes

  1. To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo

    Proportion of patients achieving ≥75% reduction in PASI score. Proportion of patients achieving a score of 0 or 1 on sPGA.

    Time frame: 16 weeks

Secondary outcomes

  1. To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast

    Proportion of patients achieving of ≥90% or 100% reduction in PASI

    Time frame: 24 weeks

  2. To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast

    Proportion of patients achieving of ≥75% reduction in PASI

    Time frame: 24 weeks

  3. To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast

    Proportion of patients achieving a score of 0 or 1 on sPGA

    Time frame: 24 weeks

  4. To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast

    Change from baseline in %BSA

    Time frame: 24 weeks

  5. To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast

    Proportion of patients achieving a score of 0 or 1 on ssPGA

    Time frame: 24 weeks

  6. To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast

    Proportion of patients achieving a score of 0

    Time frame: 24 weeks

  7. To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast

    Proportion of patients achieving a score of 0 or 1

    Time frame: 24 weeks

  8. To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo

    Change from baseline in Pruritus NRS (scale is from 0 (no pain) to 10 (severe pain)).

    Time frame: 24 weeks

  9. Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 24 weeks

  10. To characterize the pharmacokinetics of ESK-001

    Maximum \[Cmax\] and minimum \[Cmin\] plasma concentration

    Time frame: 24 weeks

07

Study locations

124 sites
  • Total Skin and Beauty Dermatology Center, PC
    Birmingham, Alabama 35203, United States
  • Chandler Clinical Trials
    Chandler, Arizona 85224, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Zenith Research Inc.
    Beverly Hills, California 90211-1705, United States
  • Raoof MD
    Encino, California 91436, United States
  • Long Beach Research Institute
    Long Beach, California 90805, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Empire Clinical Research - Pomona
    Pomona, California 91767, United States
  • Integrative Skin Science and Research
    Sacramento, California 95815, United States
  • UC San Diego
    San Diego, California 92122, United States
  • Southern California Clinical Research
    Santa Ana, California 92701, United States
  • Clinical Science Institute Dermatology Institute
    Santa Monica, California 90404, United States
  • FXM Clinical Research Ft. Lauderdale LLC
    Fort Lauderdale, Florida 33308, United States
  • Direct Helpers Research Center (DHRC)
    Hialeah, Florida 33012, United States
  • AppleMed Research Group under WCG
    Miami, Florida 33126, United States
  • FAX Pharma Clinical Research Inc
    Miami, Florida 33146, United States
  • FXM Clinical Research - Miami LLC
    Miami, Florida 33175, United States
  • Las Mercedes Medical Research
    Miami, Florida 33196, United States
  • FXM Clinical Research Miramar LLC
    Miramar, Florida 33027, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • DS Research of Southern Indiana
    Clarksville, Indiana 47129, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • DS Research of Kentucky
    Louisville, Kentucky 40241, United States
  • Michigan Center for Research Company
    Clarkston, Michigan 48346, United States
  • Henry Ford Medical Center - Farmington Road
    Detroit, Michigan 48202, United States
  • Revival Research Institute
    Troy, Michigan 48084, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • Associated Skin Care Specialists - Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • Schlessinger MD
    Omaha, Nebraska 68144, United States
  • Las Vegas Clinical Trials
    Las Vegas, Nevada 89030, United States
  • NYC Health and Hospitals Elmhurst
    Elmhurst, New York 11373, United States
  • Pioneer Clinical Research NY
    New York, New York 10016, United States
  • Cameron Dermatology
    New York, New York 10023, United States
  • DermResearchCenter of New York
    Stony Brook, New York 11790, United States
  • Asheville Clinical Trials
    Asheville, North Carolina 28803, United States
  • WDC Cosmetic and Research
    Wilmington, North Carolina 28405, United States
  • Optima Research Boardman
    Boardman, Ohio 44512, United States
  • Clinical Partners LLC
    Johnston, Rhode Island 02919, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • SMS Clinical Research
    Mesquite, Texas 75149, United States
  • Progressive Clinical Research - San Antonio
    San Antonio, Texas 78213, United States
  • Center for Clinical Studies (CCS) - Webster/Clear Lake Location
    Webster, Texas 77598, United States
  • Jordan Valley Dermatology
    South Jordan, Utah 84095, United States
  • Klinik Hietzing
    Vienna, 1220, Austria
  • Beacon Dermatology
    Calgary, Alberta T3E 0B2, Canada
  • Alberta DermaSurgery
    Edmonton, Alberta T6G 1C3, Canada
  • VIDA Dermatology/VIDA Clinical Research
    Edmonton, Alberta T6H 4J8, Canada
  • CaRe Clinic Red Deer
    Red Deer, Alberta T4P 1K4, Canada
  • Skincare Studio
    St. John's, Newfoundland and Labrador A1E 1V4, Canada
  • CCA Medical Research Corp
    Ajax, Ontario L1S 7K8, Canada
  • SimcoDerm Medical and Surgical Dermatology Center
    Barrie, Ontario L4M 7G1, Canada
  • SKiN Health
    Cobourg, Ontario K9A 0Z4, Canada
  • Guelph Dermatology Research
    Guelph, Ontario N1L 0B3, Canada
  • Mediprobe Research
    London, Ontario N5X 2P1, Canada
  • Clear Skin Dermatology
    Newmarket, Ontario L3Y 5G8, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • Rejuvination Dermatology Oakville
    Oakville, Ontario L6H 6P8, Canada
  • Toronto Research Centre
    Toronto, Ontario M3H 5Y8, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8T 1E6, Canada
  • Innovaderm
    Montreal, Quebec H2X 2V1, Canada
  • SkinSense Medical Research
    Saskatoon, Saskatchewan S7K 2C1, Canada
  • Innomedica
    Tallinn, Harju 10117, Estonia
  • Tartu University Hospital
    Tartu, Tartu 50411, Estonia
  • Center for Clinical and Basic Research AS
    Tallinn, 10128, Estonia
  • Kliiniliste Uuringute Keskus OU
    Tartu, 50106, Estonia
  • CHU de Rouen
    Rouen, Normandy 76031, France
  • Centre Azur Nice
    Nice, 06000, France
  • Polyclinique de Courlancy
    Reims, 51100, France
  • Universitatsklinikum Erlangen
    Erlangen, Bavaria 91054, Germany
  • Rosenpark Research
    Darmstadt, Hesse 64283, Germany
  • Klinikum Oldenburg
    Oldenburg, Lower Saxony 26133, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • Hautarztpraxis Dr Niesmann and Dr Othlinghaus
    Bochum, North Rhine-Westphalia 44793, Germany
  • Universitaetsklinikum Muenster
    Münster, North Rhine-Westphalia 48149, Germany
  • Dermatologische Praxis Dres Quist
    Mainz, Rhinelkand-Palatinate 55128, Germany
  • Praxis fur Dermatologie und Venerologie
    Dresden, Saxony 01097, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, Saxony 1069, Germany
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • MVZ DermaKiel GmbH
    Kiel, D-24148, Germany
  • Haut Ambulatorium Magdeburg
    Magdeburg, 39104, Germany
  • KliFOs Klinische Forschung Osnabruck
    Osnabrück, 49074, Germany
  • Bacs Kiskun County Teaching Hospital
    Kecskemét, Bács-Kiskun county 6000, Hungary
  • Borgyogyaszati Klinika Debreceni Egyetem Orvos es Egeszsegtudomenyi Centrum
    Debrecen, Hajdú-Bihar 4032, Hungary
  • DERMA B Kft
    Debrecen, Hajdú-Bihar Megye 4031, Hungary
  • DermaMed Research Kf
    Békés, Oroshaza 5900, Hungary
  • Uno Medical Trials Kft
    Budapest, 1152, Hungary
  • Orvostudomanyi Kutato es Fejleszto Kft
    Debrecen, 4027, Hungary
  • Allergo Derm Bakos Kft
    Szolnok, 5000, Hungary
  • Medmare Bt
    Veszprém, 8200, Hungary
  • Sheba Tel HaShomer Medical Centre
    Ramat Gan, 526200, Israel
  • Semigallia Ltd
    Kuldīga, Kuldigas LV3301, Latvia
  • Riga 1st Hospital
    Riga, LV1001, Latvia
  • Med Art Clinic
    Riga, LV1003, Latvia
  • Veselibas Centrs 4
    Riga, LV1003, Latvia
  • SIA Veseliba un estetika
    Riga, LV1009, Latvia
  • Veselibas Centrs 4 Filiale Dermatologijas Klinika
    Riga, LV1013, Latvia
  • Smite Aija Medical Practice in Dermatology Venereology
    Talsi, LV3201, Latvia
  • FutureMeds Krakow
    Krakow, Lesser Poland Voivodeship 31-501, Poland
  • Centrum Medyczne dr Rajzer Spolka Zoo
    Krakow, Malopolska 30-438, Poland
  • RCMed Oddział Sochaczew
    Sochaczew, Masovian Voivodeship 96-500, Poland

Showing the first 100 of 124 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided — The Sponsor Alumis Inc. is a clinical-stage biopharmaceutical company that has not yet adopted an Individual Participant Data (IPD) sharing plan.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Sep 2025, 13 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2024
First posted
Sep 19, 2024
StartActual
Aug 20, 2024
Primary completionActual
Sep 23, 2025
CompletionActual
Dec 18, 2025
Results delay requested
Aug 6, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 10 sites removed
Show 10 added (3 Puerto Rico, 3 Spain, 1 Austria, 1 Germany, 1 Latvia, 1 Poland)
  • Klinik Hietzing · Vienna, Austria
  • ISA - Interdisciplinary Study Association GmbH · Berlin, Germany
  • Smite Aija Medical Practice in Dermatology Venereology · Talsi, Latvia
  • Luxderm · Lublin, Poland
  • Centro Reumatologico de Caguas · Caguas, Puerto Rico
  • Ponce Medical School Foundation Inc · Ponce, Puerto Rico
  • Clinical Research Puerto Rico · Ponce, Puerto Rico
  • University General Hospital Dr Balmis · Alicante, Spain
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
Show 10 removed
  • Klinik Hietzing · Vienna, Austria
  • ISA - Interdisciplinary Study Association GmbH · Berlin, Germany
  • Smite Aija Medical Practice in Dermatology Venereology · Talsi, Latvia
  • Luxderm · Lublin, Poland
  • Centro Reumatologico de Caguas · Caguas, Puerto Rico
  • Ponce Medical School Foundation Inc · Ponce, Puerto Rico
  • Clinical Research Puerto Rico · Ponce, Puerto Rico
  • University General Hospital Dr Balmis · Alicante, Spain
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    10 sites added, 10 sites removed
    Show 10 added (3 Puerto Rico, 3 Spain, 1 Austria, 1 Germany, 1 Latvia, 1 Poland)
    • Klinik Hietzing · Vienna, Austria
    • ISA - Interdisciplinary Study Association GmbH · Berlin, Germany
    • Smite Aija Medical Practice in Dermatology Venereology · Talsi, Latvia
    • Luxderm · Lublin, Poland
    • Centro Reumatologico de Caguas · Caguas, Puerto Rico
    • Ponce Medical School Foundation Inc · Ponce, Puerto Rico
    • Clinical Research Puerto Rico · Ponce, Puerto Rico
    • University General Hospital Dr Balmis · Alicante, Spain
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    Show 10 removed
    • Klinik Hietzing · Vienna, Austria
    • ISA - Interdisciplinary Study Association GmbH · Berlin, Germany
    • Smite Aija Medical Practice in Dermatology Venereology · Talsi, Latvia
    • Luxderm · Lublin, Poland
    • Centro Reumatologico de Caguas · Caguas, Puerto Rico
    • Ponce Medical School Foundation Inc · Ponce, Puerto Rico
    • Clinical Research Puerto Rico · Ponce, Puerto Rico
    • University General Hospital Dr Balmis · Alicante, Spain
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06588738
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 20, 2024
Primary completion
Sep 23, 2025
Completion
Dec 18, 2025
Last update
Oct 28, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion